patient_id stringlengths 12 12 | record_id stringlengths 11 11 | cancer_type stringclasses 1
value | histology stringclasses 3
values | stage_at_diagnosis stringclasses 3
values | driver_mutation stringclasses 7
values | pd_l1_tps_percent int64 5 41 | tmb_mutations_per_mb float64 1.5 25 | age_at_diagnosis int64 38 90 | sex stringclasses 2
values | ecog_performance_status int64 0 4 | smoking_pack_years int64 0 111 | primary_tumor_size_cm float64 2 10 | metastatic_sites_count int64 0 11 | first_line_regimen stringclasses 6
values | overall_survival_months float64 4 83 | censored bool 2
classes | msi_status stringclasses 2
values | record_generation_timestamp stringdate 2026-03-15 05:35:56 2026-03-15 05:36:02 | synthetic_source stringclasses 1
value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ANODE_908368 | REC_0006501 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 17 | 8.4 | 59 | male | 0 | 7 | 5.8 | 7 | alectinib 600 mg BID | 15.2 | false | MSS | 2026-03-15T05:35:58.449853+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_121831 | REC_0006502 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 20 | 7.2 | 76 | female | 2 | 29 | 5.5 | 1 | carboplatin + paclitaxel + pembrolizumab | 18.3 | false | MSS | 2026-03-15T05:35:58.450087+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_700311 | REC_0006503 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 25 | 9.7 | 80 | male | 1 | 24 | 5 | 2 | osimertinib 80 mg daily | 15.7 | false | MSS | 2026-03-15T05:35:58.450323+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_834063 | REC_0006504 | Non-small cell lung cancer | Adenocarcinoma | III | ROS1 fusion | 24 | 8.2 | 81 | female | 2 | 13 | 4.8 | 0 | entrectinib 600 mg daily | 23.2 | true | MSS | 2026-03-15T05:35:58.450552+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_511458 | REC_0006505 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 25 | 9.3 | 64 | female | 1 | 19 | 5.6 | 1 | sotorasib 960 mg daily | 16.1 | true | MSS | 2026-03-15T05:35:58.450785+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_244338 | REC_0006506 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 17 | 3 | 70 | female | 2 | 16 | 4.4 | 1 | alectinib 600 mg BID | 22.7 | false | MSS | 2026-03-15T05:35:58.451013+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_257492 | REC_0006507 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 28 | 5.9 | 71 | male | 2 | 8 | 5.5 | 2 | alectinib 600 mg BID | 26.7 | true | MSS | 2026-03-15T05:35:58.451246+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_393281 | REC_0006508 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 20 | 15 | 72 | female | 1 | 14 | 5.6 | 7 | entrectinib 600 mg daily | 8.4 | true | MSI-H | 2026-03-15T05:35:58.451477+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_641072 | REC_0006509 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 33 | 8.6 | 70 | male | 2 | 11 | 5.6 | 1 | sotorasib 960 mg daily | 26.8 | true | MSS | 2026-03-15T05:35:58.451709+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_450599 | REC_0006510 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 34 | 7.6 | 77 | female | 3 | 3 | 5.5 | 2 | sotorasib 960 mg daily | 9.4 | true | MSS | 2026-03-15T05:35:58.451940+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_523460 | REC_0006511 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 33 | 13.2 | 70 | male | 3 | 22 | 5.8 | 5 | alectinib 600 mg BID | 13.3 | false | MSS | 2026-03-15T05:35:58.452204+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_614832 | REC_0006512 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 31 | 10.9 | 75 | female | 2 | 14 | 5.2 | 2 | alectinib 600 mg BID | 14.8 | true | MSS | 2026-03-15T05:35:58.452438+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_676143 | REC_0006513 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 22 | 3.9 | 70 | female | 3 | 64 | 7 | 6 | carboplatin + paclitaxel + pembrolizumab | 13.5 | true | MSS | 2026-03-15T05:35:58.452668+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_610004 | REC_0006514 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 25 | 10.2 | 66 | female | 1 | 11 | 8.2 | 6 | entrectinib 600 mg daily | 9.7 | false | MSI-H | 2026-03-15T05:35:58.452948+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_843862 | REC_0006515 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 31 | 10.7 | 57 | male | 1 | 14 | 5 | 2 | alectinib 600 mg BID | 19 | true | MSI-H | 2026-03-15T05:35:58.453191+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_416353 | REC_0006516 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 24 | 13.8 | 65 | female | 0 | 12 | 4.3 | 2 | osimertinib 80 mg daily | 23 | true | MSI-H | 2026-03-15T05:35:58.453426+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_516972 | REC_0006517 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 30 | 10.6 | 65 | male | 1 | 12 | 6.2 | 5 | sotorasib 960 mg daily | 7.1 | true | MSI-H | 2026-03-15T05:35:58.453662+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_884332 | REC_0006518 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 23 | 12.2 | 68 | female | 0 | 18 | 7.2 | 6 | sotorasib 960 mg daily | 13.5 | false | MSI-H | 2026-03-15T05:35:58.453894+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_875996 | REC_0006519 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 21 | 4.3 | 66 | female | 1 | 40 | 7.8 | 5 | carboplatin + paclitaxel + pembrolizumab | 12 | false | MSS | 2026-03-15T05:35:58.454128+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_658080 | REC_0006520 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 26 | 15.5 | 67 | male | 0 | 23 | 4.9 | 6 | osimertinib 80 mg daily | 4.9 | true | MSI-H | 2026-03-15T05:35:58.454363+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_317670 | REC_0006521 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 33 | 15.5 | 62 | male | 0 | 7 | 4.6 | 1 | sotorasib 960 mg daily | 24.2 | false | MSS | 2026-03-15T05:35:58.454597+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_691636 | REC_0006522 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 25 | 10.6 | 66 | female | 0 | 15 | 6.1 | 5 | osimertinib 80 mg daily | 16.5 | false | MSS | 2026-03-15T05:35:58.454833+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_133341 | REC_0006523 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 22 | 11.3 | 63 | female | 0 | 19 | 7.2 | 6 | osimertinib 80 mg daily | 8.4 | false | MSS | 2026-03-15T05:35:58.455070+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_562877 | REC_0006524 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 22 | 5.3 | 83 | female | 3 | 50 | 6.6 | 6 | carboplatin + paclitaxel + pembrolizumab | 11.5 | true | MSS | 2026-03-15T05:35:58.455296+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_282460 | REC_0006525 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 21 | 14.8 | 63 | female | 0 | 20 | 4.2 | 2 | osimertinib 80 mg daily | 15.8 | true | MSS | 2026-03-15T05:35:58.455533+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_637970 | REC_0006526 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 35 | 8.6 | 59 | male | 1 | 15 | 4 | 2 | alectinib 600 mg BID | 16.2 | true | MSS | 2026-03-15T05:35:58.455763+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_226110 | REC_0006527 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 31 | 15.4 | 65 | female | 1 | 20 | 4.5 | 2 | entrectinib 600 mg daily | 17.5 | false | MSS | 2026-03-15T05:35:58.456041+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_277464 | REC_0006528 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 25 | 9.6 | 63 | male | 1 | 10 | 5.6 | 2 | osimertinib 80 mg daily | 10.7 | false | MSS | 2026-03-15T05:35:58.456395+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_455270 | REC_0006529 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 22 | 10 | 75 | female | 0 | 15 | 6 | 3 | alectinib 600 mg BID | 11.4 | false | MSS | 2026-03-15T05:35:58.456634+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_807131 | REC_0006530 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 13 | 5.3 | 77 | female | 1 | 20 | 5.7 | 1 | osimertinib 80 mg daily | 19.5 | false | MSS | 2026-03-15T05:35:58.456867+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_756140 | REC_0006531 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 30 | 5 | 81 | female | 1 | 44 | 8 | 1 | carboplatin + paclitaxel + pembrolizumab | 34 | false | MSS | 2026-03-15T05:35:58.457097+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_144425 | REC_0006532 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 25 | 12.7 | 59 | male | 0 | 12 | 5.6 | 7 | osimertinib 80 mg daily | 14.7 | true | MSI-H | 2026-03-15T05:35:58.457330+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_814909 | REC_0006533 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 23 | 13.1 | 70 | male | 0 | 7 | 6 | 3 | entrectinib 600 mg daily | 19.1 | true | MSI-H | 2026-03-15T05:35:58.457567+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_831699 | REC_0006534 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 25 | 14.5 | 63 | female | 0 | 13 | 7.6 | 5 | alectinib 600 mg BID | 14.9 | true | MSS | 2026-03-15T05:35:58.457801+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_743333 | REC_0006535 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 20 | 15.2 | 69 | female | 1 | 18 | 7.3 | 1 | osimertinib 80 mg daily | 18.6 | true | MSS | 2026-03-15T05:35:58.458036+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_759623 | REC_0006536 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 28 | 11 | 66 | female | 1 | 13 | 3.8 | 6 | alectinib 600 mg BID | 12.1 | false | MSS | 2026-03-15T05:35:58.458273+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_294649 | REC_0006537 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 22 | 6.6 | 59 | female | 1 | 23 | 6.6 | 2 | carboplatin + paclitaxel + pembrolizumab | 17.7 | true | MSS | 2026-03-15T05:35:58.458502+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_670001 | REC_0006538 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 25 | 11.9 | 77 | female | 1 | 26 | 3.1 | 8 | osimertinib 80 mg daily | 4.1 | true | MSI-H | 2026-03-15T05:35:58.458733+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_267826 | REC_0006539 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 29 | 10.9 | 69 | female | 0 | 15 | 5.2 | 5 | pembrolizumab 200 mg q3w | 14.7 | true | MSI-H | 2026-03-15T05:35:58.458964+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_404769 | REC_0006540 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 28 | 13.4 | 60 | female | 1 | 16 | 5 | 1 | osimertinib 80 mg daily | 10.4 | true | MSI-H | 2026-03-15T05:35:58.459242+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_672088 | REC_0006541 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 28 | 10.7 | 46 | male | 0 | 15 | 7 | 6 | alectinib 600 mg BID | 9.4 | false | MSI-H | 2026-03-15T05:35:58.459479+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_117105 | REC_0006542 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 25 | 3.5 | 78 | female | 2 | 14 | 4.8 | 5 | entrectinib 600 mg daily | 14.9 | false | MSS | 2026-03-15T05:35:58.459707+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_854456 | REC_0006543 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 31 | 3.8 | 60 | female | 0 | 66 | 6.7 | 4 | pembrolizumab 200 mg q3w | 10.7 | true | MSS | 2026-03-15T05:35:58.459944+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_207621 | REC_0006544 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 27 | 6.2 | 78 | male | 1 | 16 | 3.9 | 4 | osimertinib 80 mg daily | 12 | false | MSS | 2026-03-15T05:35:58.460229+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_764200 | REC_0006545 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 25 | 12.1 | 70 | male | 1 | 15 | 2.8 | 5 | osimertinib 80 mg daily | 8.6 | false | MSI-H | 2026-03-15T05:35:58.460481+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_544187 | REC_0006546 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 20 | 6.5 | 65 | female | 1 | 13 | 3.9 | 4 | osimertinib 80 mg daily | 11.9 | true | MSS | 2026-03-15T05:35:58.460715+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_282912 | REC_0006547 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 27 | 8.4 | 62 | male | 1 | 63 | 5 | 1 | carboplatin + paclitaxel + pembrolizumab | 15.1 | false | MSS | 2026-03-15T05:35:58.460948+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_338230 | REC_0006548 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 35 | 17.6 | 77 | female | 1 | 16 | 7 | 2 | entrectinib 600 mg daily | 9.4 | true | MSI-H | 2026-03-15T05:35:58.461182+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_469918 | REC_0006549 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 25 | 10.5 | 63 | male | 0 | 19 | 5.9 | 3 | osimertinib 80 mg daily | 4 | true | MSS | 2026-03-15T05:35:58.461418+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_878626 | REC_0006550 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 22 | 6.8 | 72 | female | 2 | 54 | 4.7 | 3 | pembrolizumab 200 mg q3w | 14.5 | true | MSS | 2026-03-15T05:35:58.461648+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_246194 | REC_0006551 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 29 | 9.9 | 79 | female | 1 | 19 | 3.7 | 2 | pembrolizumab 200 mg q3w | 9.8 | false | MSS | 2026-03-15T05:35:58.461876+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_834145 | REC_0006552 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 28 | 2.9 | 78 | female | 3 | 11 | 5.4 | 5 | pembrolizumab 200 mg q3w | 11.2 | false | MSS | 2026-03-15T05:35:58.462101+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_623261 | REC_0006553 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 26 | 10.8 | 77 | female | 1 | 20 | 3.5 | 8 | sotorasib 960 mg daily | 12.8 | false | MSS | 2026-03-15T05:35:58.462377+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_571729 | REC_0006554 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 22 | 9.7 | 78 | female | 2 | 6 | 4.4 | 2 | osimertinib 80 mg daily | 12.9 | false | MSS | 2026-03-15T05:35:58.462609+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_113500 | REC_0006555 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 24 | 14.2 | 70 | female | 1 | 10 | 7 | 1 | sotorasib 960 mg daily | 4 | false | MSS | 2026-03-15T05:35:58.462842+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_515786 | REC_0006556 | Non-small cell lung cancer | Large cell carcinoma | IVA | None (PD-L1 high) | 26 | 4.4 | 61 | male | 1 | 7 | 5.8 | 1 | pembrolizumab 200 mg q3w | 14.5 | true | MSS | 2026-03-15T05:35:58.463073+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_980705 | REC_0006557 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 25 | 16.9 | 62 | male | 1 | 15 | 4.3 | 5 | entrectinib 600 mg daily | 16.8 | false | MSS | 2026-03-15T05:35:58.463309+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_726734 | REC_0006558 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 21 | 7 | 81 | female | 2 | 49 | 6.1 | 9 | carboplatin + paclitaxel + pembrolizumab | 10.3 | false | MSS | 2026-03-15T05:35:58.463539+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_435604 | REC_0006559 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 29 | 8.8 | 74 | female | 2 | 33 | 5.2 | 6 | carboplatin + paclitaxel + pembrolizumab | 6 | true | MSS | 2026-03-15T05:35:58.463776+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_348607 | REC_0006560 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 21 | 7.4 | 66 | male | 0 | 15 | 5.1 | 2 | sotorasib 960 mg daily | 17.9 | true | MSS | 2026-03-15T05:35:58.464010+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_843785 | REC_0006561 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 15 | 14.9 | 74 | female | 2 | 4 | 5.9 | 1 | osimertinib 80 mg daily | 16.6 | false | MSS | 2026-03-15T05:35:58.464271+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_549521 | REC_0006562 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 36 | 12.2 | 64 | female | 1 | 21 | 5.8 | 8 | alectinib 600 mg BID | 17 | true | MSS | 2026-03-15T05:35:58.464511+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_881505 | REC_0006563 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 26 | 7.5 | 56 | male | 1 | 11 | 4.4 | 6 | sotorasib 960 mg daily | 10.6 | false | MSS | 2026-03-15T05:35:58.464743+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_821097 | REC_0006564 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 15 | 6.1 | 63 | male | 1 | 8 | 6 | 5 | pembrolizumab 200 mg q3w | 12.6 | false | MSS | 2026-03-15T05:35:58.464977+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_263931 | REC_0006565 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 25 | 7.3 | 71 | female | 2 | 13 | 4.9 | 5 | osimertinib 80 mg daily | 6.9 | false | MSS | 2026-03-15T05:35:58.465205+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_239878 | REC_0006566 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 21 | 11.6 | 65 | female | 0 | 11 | 5.2 | 7 | osimertinib 80 mg daily | 10.8 | false | MSS | 2026-03-15T05:35:58.465483+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_363666 | REC_0006567 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 25 | 12.7 | 74 | female | 1 | 14 | 4.2 | 4 | sotorasib 960 mg daily | 19.3 | true | MSI-H | 2026-03-15T05:35:58.465724+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_988483 | REC_0006568 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 28 | 12.5 | 69 | female | 1 | 13 | 6.4 | 6 | osimertinib 80 mg daily | 10.1 | true | MSS | 2026-03-15T05:35:58.465957+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_459034 | REC_0006569 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 22 | 11.5 | 75 | female | 1 | 24 | 2.5 | 1 | entrectinib 600 mg daily | 6.6 | false | MSS | 2026-03-15T05:35:58.466188+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_222620 | REC_0006570 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 29 | 9.5 | 66 | female | 1 | 11 | 4.7 | 2 | entrectinib 600 mg daily | 21.5 | false | MSS | 2026-03-15T05:35:58.466420+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_513568 | REC_0006571 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 27 | 5.9 | 83 | female | 2 | 23 | 5.7 | 2 | osimertinib 80 mg daily | 8.8 | false | MSS | 2026-03-15T05:35:58.466647+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_900233 | REC_0006572 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 25 | 13.5 | 57 | male | 0 | 3 | 5.1 | 6 | osimertinib 80 mg daily | 13.2 | true | MSI-H | 2026-03-15T05:35:58.466881+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_871452 | REC_0006573 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 16 | 14.6 | 62 | male | 1 | 16 | 3.1 | 6 | sotorasib 960 mg daily | 11.5 | true | MSS | 2026-03-15T05:35:58.467115+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_208239 | REC_0006574 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 27 | 18 | 57 | male | 1 | 16 | 4.3 | 7 | osimertinib 80 mg daily | 12.8 | false | MSI-H | 2026-03-15T05:35:58.467349+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_529855 | REC_0006575 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 26 | 12.7 | 61 | male | 0 | 26 | 4.3 | 5 | alectinib 600 mg BID | 9 | true | MSI-H | 2026-03-15T05:35:58.467583+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_943042 | REC_0006576 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 31 | 5.8 | 83 | male | 2 | 19 | 6.2 | 6 | alectinib 600 mg BID | 12.2 | false | MSS | 2026-03-15T05:35:58.467812+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_497182 | REC_0006577 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 25 | 8.5 | 71 | female | 3 | 17 | 5.6 | 3 | osimertinib 80 mg daily | 20.8 | true | MSS | 2026-03-15T05:35:58.468037+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_611146 | REC_0006578 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 18 | 14.9 | 68 | female | 1 | 7 | 6 | 1 | entrectinib 600 mg daily | 13.5 | true | MSI-H | 2026-03-15T05:35:58.468293+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_618298 | REC_0006579 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 21 | 6.8 | 69 | female | 0 | 18 | 7.7 | 4 | sotorasib 960 mg daily | 13.1 | true | MSS | 2026-03-15T05:35:58.468566+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_899499 | REC_0006580 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 26 | 9 | 68 | female | 0 | 20 | 5.7 | 2 | sotorasib 960 mg daily | 13.5 | true | MSS | 2026-03-15T05:35:58.468796+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_261104 | REC_0006581 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 25 | 5.2 | 64 | female | 1 | 11 | 3.8 | 5 | osimertinib 80 mg daily | 9.8 | true | MSS | 2026-03-15T05:35:58.469028+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_192841 | REC_0006582 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 22 | 10.2 | 83 | female | 2 | 18 | 8 | 2 | sotorasib 960 mg daily | 20.9 | true | MSI-H | 2026-03-15T05:35:58.469265+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_113346 | REC_0006583 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 26 | 4 | 63 | female | 0 | 32 | 6 | 3 | carboplatin + paclitaxel + pembrolizumab | 4 | true | MSS | 2026-03-15T05:35:58.469496+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_201849 | REC_0006584 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 11 | 14.6 | 65 | female | 1 | 7 | 4.5 | 1 | alectinib 600 mg BID | 24.2 | false | MSI-H | 2026-03-15T05:35:58.469726+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_384145 | REC_0006585 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 24 | 11.6 | 72 | female | 2 | 22 | 4 | 2 | sotorasib 960 mg daily | 20.7 | false | MSI-H | 2026-03-15T05:35:58.469958+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_587795 | REC_0006586 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 32 | 4.9 | 55 | male | 1 | 39 | 4.3 | 6 | carboplatin + paclitaxel + pembrolizumab | 6.2 | false | MSS | 2026-03-15T05:35:58.470187+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_230181 | REC_0006587 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 21 | 4 | 58 | male | 1 | 40 | 3.6 | 6 | carboplatin + paclitaxel + pembrolizumab | 12.3 | false | MSS | 2026-03-15T05:35:58.470422+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_184685 | REC_0006588 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 21 | 5.5 | 66 | female | 0 | 15 | 5.1 | 7 | pembrolizumab 200 mg q3w | 4 | true | MSS | 2026-03-15T05:35:58.470650+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_957394 | REC_0006589 | Non-small cell lung cancer | Adenocarcinoma | III | EGFR exon 19 deletion | 33 | 5.9 | 72 | female | 2 | 15 | 5 | 0 | osimertinib 80 mg daily | 30.1 | true | MSS | 2026-03-15T05:35:58.470882+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_505501 | REC_0006590 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 29 | 11.3 | 66 | female | 1 | 21 | 3.7 | 1 | sotorasib 960 mg daily | 27.8 | false | MSI-H | 2026-03-15T05:35:58.471111+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_734868 | REC_0006591 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 22 | 11.5 | 76 | female | 0 | 19 | 7 | 6 | sotorasib 960 mg daily | 9.6 | false | MSS | 2026-03-15T05:35:58.471347+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_377995 | REC_0006592 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 30 | 6.1 | 65 | female | 0 | 54 | 7.3 | 8 | pembrolizumab 200 mg q3w | 4 | false | MSS | 2026-03-15T05:35:58.471624+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_843665 | REC_0006593 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 27 | 17.7 | 73 | female | 1 | 15 | 6.9 | 4 | pembrolizumab 200 mg q3w | 18.4 | false | MSI-H | 2026-03-15T05:35:58.471860+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_962987 | REC_0006594 | Non-small cell lung cancer | Large cell carcinoma | IVA | None (PD-L1 high) | 28 | 8.1 | 64 | female | 0 | 10 | 6.6 | 1 | pembrolizumab 200 mg q3w | 21.6 | true | MSS | 2026-03-15T05:35:58.472132+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_144337 | REC_0006595 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 31 | 16.8 | 70 | male | 1 | 11 | 6.9 | 6 | osimertinib 80 mg daily | 8.8 | false | MSI-H | 2026-03-15T05:35:58.472377+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_865679 | REC_0006596 | Non-small cell lung cancer | Adenocarcinoma | III | ALK fusion | 23 | 14.9 | 62 | male | 1 | 6 | 5.8 | 0 | alectinib 600 mg BID | 19.1 | false | MSI-H | 2026-03-15T05:35:58.472622+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_510834 | REC_0006597 | Non-small cell lung cancer | Adenocarcinoma | III | EGFR exon 19 deletion | 25 | 14.2 | 73 | male | 0 | 23 | 6.7 | 0 | osimertinib 80 mg daily | 21.5 | true | MSI-H | 2026-03-15T05:35:58.472860+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_981149 | REC_0006598 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 30 | 14.5 | 71 | female | 2 | 15 | 6.8 | 6 | osimertinib 80 mg daily | 13.9 | true | MSI-H | 2026-03-15T05:35:58.473088+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_728603 | REC_0006599 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 26 | 12.1 | 78 | male | 1 | 15 | 6.4 | 5 | osimertinib 80 mg daily | 11.6 | true | MSI-H | 2026-03-15T05:35:58.473325+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_540071 | REC_0006600 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None (PD-L1 high) | 25 | 6.8 | 71 | male | 1 | 51 | 4.9 | 1 | pembrolizumab 200 mg q3w | 19.9 | true | MSS | 2026-03-15T05:35:58.473558+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.